Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
Jazz Pharmaceuticals (JAZZ) PT Raised to $199 at BMO Capital
February 28, 2018 6:59 AM ESTBMO Capital raised its price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $199.00 (from $196.00) while maintaining an Outperform rating.
Analyst Gary Nachman commented, "JAZZ reported 4Q revenue of $436mm vs. BMO/consensus of $438mm/442mm and adj. EPS of $2.95 vs. BMO/consensus of... More
Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 6c; Guides FY18 Relatively In-Line
February 27, 2018 4:08 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.95, $0.06 worse than the analyst estimate of $3.01. Revenue for the quarter came in at $436.4 million versus the consensus estimate of $441.31 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2018 EPS of $12.65-$13.25, versus the consensus of $13.07.... More
